Lantheus (LNTH) 10-Q 29 Apr 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	Apr. 22, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-36569
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2318913
Entity Address, Address Line One	331 Treble Cove Road
Entity Address, Postal Zip Code	01862
Entity Address, City or Town	North Billerica,
Entity Address, State or Province	MA
City Area Code	(978)
Local Phone Number	671-8001
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	LNTH
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		68,634,063
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001521036
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 105,355	$ 98,508
Accounts receivable, net	172,283	89,336
Inventory	34,249	35,129
Other current assets	12,860	12,818
Total current assets	324,747	235,791
Property, plant and equipment, net	116,959	116,772
Intangibles, net	340,204	348,510
Goodwill	61,189	61,189
Deferred tax assets, net	47,868	62,764
Other long-term assets	42,199	38,758
Total assets	933,166	863,784
Current liabilities
Current portion of long-term debt and other borrowings	12,878	11,642
Accounts payable	22,383	20,787
Accrued expenses and other liabilities	142,396	58,068
Total current liabilities	177,657	90,497
Asset retirement obligations	21,514	20,833
Long-term debt, net and other borrowings	159,369	163,121
Other long-term liabilities	58,776	124,894
Total liabilities	417,316	399,345
Commitments and contingencies (See Note 19)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0
Common stock ($0.01 par value, 250,000 shares authorized; 68,570 and 67,739 shares issued and outstanding, respectively)	686	677
Additional paid-in capital	691,516	685,472
Accumulated deficit	(178,263)	(221,225)
Accumulated other comprehensive income (loss)	1,911	(485)
Total stockholders’ equity	515,850	464,439
Total liabilities and stockholders’ equity	$ 933,166	$ 863,784

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	68,570,000	67,739,000
Common stock, shares outstanding (in shares)	68,570,000	67,739,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues	$ 208,880	$ 92,509
Cost of goods sold	79,810	51,479
Gross profit	129,070	41,030
Operating expenses
Sales and marketing	20,354	14,173
General and administrative	37,588	16,138
Research and development	12,203	10,360
Total operating expenses	70,145	40,671
Gain on sale of assets	0	15,263
Operating income	58,925	15,622
Interest expense	1,509	2,718
Gain on extinguishment of debt	0	(889)
Other income	(485)	(549)
Income before income taxes	57,901	14,342
Income tax expense	14,939	5,334
Net income	$ 42,962	$ 9,008
Net income per common share:
Basic (in dollars per share)	$ 0.63	$ 0.13
Diluted (in dollars per share)	$ 0.61	$ 0.13
Weighted-average common shares outstanding:
Basic (in shares)	68,008	67,094
Diluted (in shares)	70,051	67,714

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 42,962	$ 9,008
Other comprehensive income:
Foreign currency translation	140	102
Unrealized gain on cash flow hedges, net of tax	2,256	706
Total other comprehensive income	2,396	808
Comprehensive income	$ 45,358	$ 9,816

Condensed Consolidated Changes

Condensed Consolidated Changes In Stockholders' Equity (Statement) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2020		66,875
Beginning balance at Dec. 31, 2020	$ 514,205	$ 669	$ 665,530	$ (149,946)	$ (2,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	9,008			9,008
Other comprehensive income	808				808
Stock option exercises and employee stock plan purchases (in shares)		155
Stock option exercises and employee stock plan purchases	2,380	$ 1	2,379
Vesting of restricted stock awards and units (in shares)		489
Vesting of restricted stock awards and units	0	$ 5	(5)
Shares withheld to cover taxes (in shares)		(85)
Shares withheld to cover taxes	(1,599)	$ (1)	(1,598)
Stock-based compensation	3,317		3,317
Ending balance (in shares) at Mar. 31, 2021		67,434
Ending balance at Mar. 31, 2021	528,119	$ 674	669,623	(140,938)	(1,240)
Beginning balance (in shares) at Dec. 31, 2021		67,739
Beginning balance at Dec. 31, 2021	464,439	$ 677	685,472	(221,225)	(485)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	42,962			42,962
Other comprehensive income	2,396				2,396
Stock option exercises and employee stock plan purchases (in shares)		296
Stock option exercises and employee stock plan purchases	5,934	$ 3	5,931
Vesting of restricted stock awards and units (in shares)		645
Vesting of restricted stock awards and units	0	$ 7	(7)
Shares withheld to cover taxes (in shares)		(110)
Shares withheld to cover taxes	(5,504)	$ (1)	(5,503)
Stock-based compensation	5,623		5,623
Ending balance (in shares) at Mar. 31, 2022		68,570
Ending balance at Mar. 31, 2022	$ 515,850	$ 686	$ 691,516	$ (178,263)	$ 1,911

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Operating activities
Net income	$ 42,962	$ 9,008
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion	11,786	8,123
ARO acceleration	293	0
Amortization of debt related costs	246	(61)
Changes in fair value of contingent assets and liabilities	18,400	300
Gain on extinguishment of debt	0	(889)
Provision for excess and obsolete inventory	2,519	1,395
Stock-based compensation	5,623	3,317
Gain on sale of assets	0	(15,263)
Deferred taxes	14,180	4,581
Long-term income tax receivable	(396)	(573)
Long-term income tax payable and other long-term liabilities	779	728
Other	829	655
(Decreases) increases in cash from operating assets and liabilities:
Accounts receivable	(85,155)	(2,346)
Inventory	(1,634)	3,889
Other current assets	(104)	(536)
Other long-term assets	(533)	0
Accounts payable	1,506	4,110
Accrued expenses and other liabilities	(1,037)	(6,620)
Net cash provided by operating activities	10,264	9,818
Investing activities
Capital expenditures	(3,190)	(2,520)
Proceeds from sale of assets, net	1,800	15,823
Net cash (used in) provided by investing activities	(1,390)	13,303
Financing activities
Payments on long-term debt and other borrowings	(2,609)	(35,572)
Proceeds from stock option exercises	5,357	2,043
Proceeds from issuance of common stock	577	337
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(5,504)	(1,599)
Net cash used in financing activities	(2,179)	(34,791)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash	151	(21)
Net increase (decrease) in cash, cash equivalents and restricted cash	6,846	(11,691)
Cash, cash equivalents and restricted cash, beginning of period	100,651	82,694
Cash, cash equivalents and restricted cash, end of period	107,497	71,003
Reconciliation to amounts within the condensed consolidated balance sheets
Cash and cash equivalents	105,355	68,861
Restricted cash included in other long-term assets	2,142	2,142
Cash, cash equivalents and restricted cash at end of period	$ 107,497	$ 71,003

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022. Progenics Acquisition On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). Subsequently, on June 22, 2020, Holdings contributed all of the capital stock of Progenics to LMI, thereby making Progenics an indirect subsidiary of Holdings. In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent began in June 2021. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company currently estimates could be approximately $100.0 million). The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a “Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested or unvested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Replacement Stock Option converted at an exchange ratio determined based on the average of the

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting PoliciesRecent Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2022

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers The following table summarizes revenue by revenue source as follows: Three Months Ended Major Products/Service Lines (in thousands) 2022 2021 Product revenue, net (1) $ 180,009 $ 87,319 License and royalty revenues (2) 28,871 5,190 Total revenues $ 208,880 $ 92,509 ________________________________ (1) The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products. (2) The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement. The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other revenue includes strategic partnerships and other arrangements related to other products of the Company, such as royalty revenue from our license of RELISTOR. On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc. (“AAA”), Endocyte, Inc. (“Endocyte”) and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with the German litigation (please refer to Note 19 “Commitments and Contingencies”) and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers , assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022. Revenue by product category on a net basis is as follows: Three Months Ended (in thousands) 2022 2021 DEFINITY $ 58,328 $ 55,971 TechneLite 22,605 22,800 Other precision diagnostics 5,265 6,984 Total precision diagnostics 86,198 85,755 PYLARIFY 92,777 — Other radiopharmaceutical oncology 1,327 1,500 Total radiopharmaceutical oncology 94,104 1,500 Strategic partnerships and other revenue 28,578 5,254 Total revenues $ 208,880 $ 92,509 The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). • Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data. The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market. The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis: March 31, 2022 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 38,986 $ 38,986 $ — $ — Interest rate swaps 3,387 — 3,387 — Contingent receivable 8,900 — — 8,900 Total assets $ 51,273 $ 38,986 $ 3,387 $ 8,900 Liabilities: Contingent consideration liabilities $ 104,200 $ — $ — $ 104,200 Total liabilities $ 104,200 $ — $ — $ 104,200 December 31, 2021 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 40,140 $ 40,140 $ — $ — Interest rate swaps 357 — 357 — Contingent receivable 9,300 — — 9,300 Total assets $ 49,797 $ 40,140 $ 357 $ 9,300 Liabilities: Contingent consideration liabilities $ 86,200 $ — $ — $ 86,200 Total liabilities $ 86,200 $ — $ — $ 86,200 During the three months ended March 31, 2022, there were no transfers into or out of Level 3. As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success. As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap (which the Company currently estimates could be approximately $100.0 million). Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success. Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities. The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022. Fair Value at Assumptions (in thousands) March 31, 2022 December 31, 2021 Valuation Technique Unobservable Input March 31, 2022 December 31, 2021 Contingent receivable: Regulatory milestone $ 2,500 $ 2,500 Probability adjusted discounted cash flow model Period of expected milestone achievement 2022 2022 Probability of success 70 % 70 % Discount rate 18 % 17 % Royalties 6,400 6,800 Probability adjusted discounted cash flow model Probability of success 10% - 60% 10% - 60% Discount rate 18 % 17 % Total $ 8,900 $ 9,300 Fair Value at Assumptions (in thousands) March 31, 2022 December 31, 2021 Valuation Technique Unobservable Input March 31, 2022 December 31, 2021 Contingent consideration liability: Net sales targets - PYLARIFY (CVRs) $ 91,700 $ 73,200 Monte Carlo simulation Period of expected milestone achievement and sales targets 2022 - 2023 2022 - 2023 Discount rate 18 % 17 % 1095 commercialization milestone 1,800 1,900 Probability adjusted discounted cash flow model Period of expected milestone achievement 2026 2026 Probability of success 40 % 40 % Discount rate 2.1 % 1.3 % Net sales targets - AZEDRA and 1095 10,700 11,100 Monte Carlo simulation Probability of success and sales targets 40% - 100% 40% - 100% Discount rate 17% - 18% 16% - 17% Total $ 104,200 $ 86,200 For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated: Financial Assets Financial Liabilities (in thousands) Three Months Ended Three Months Ended 2022 2021 2022 2021 Fair value, beginning of period $ 9,300 $ 11,300 $ 86,200 $ 15,800 Changes in fair value included in net income (400) 900 18,000 1,200 Fair value, end of period $ 8,900 $ 12,200 $ 104,200 $ 17,000

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company calculates income taxes at the end of each reporting period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below: Three Months Ended (in thousands) 2022 2021 Income tax expense $ 14,939 $ 5,334 The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company assessed the need for a valuation allowance against certain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to retain other valuation allowances of $1.2 million against the net deferred tax assets of its U.K. subsidiary, and $2.0 million against the net deferred tax assets of its Sweden subsidiary. In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments to be paid on behalf of the Company by BMS, net of actual tax benefits received by the Company. The tax indemnification receivable is recorded within other long-term assets. In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities. The Company finalized the accounting for the Progenics Acquisition for income taxes in the first quarter of 2021 resulting in a reduction of deferred tax assets, primarily related to state research credit carryforwards and an increase to goodwill of $2.6 million.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following: (in thousands) March 31, December 31, Raw materials $ 13,861 $ 15,505 Work in process 13,071 13,042 Finished goods 7,317 6,582 Total inventory $ 34,249 $ 35,129 Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of December 31, 2021, the Company had $6.1 million of such product costs included in inventories related to DEFINITY that had been manufactured through the Company’s in-house manufacturing capabilities. The Company received regulatory approval for the manufacture of DEFINITY at its new in-house manufacturing facility during the first quarter of 2022 and has no inventory pending regulatory approval as of March 31, 2022.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net, consisted of the following: (in thousands) March 31, December 31, Land $ 13,450 $ 13,450 Buildings 73,560 73,559 Machinery, equipment and fixtures 84,983 83,608 Computer software 24,766 24,384 Construction in progress 12,186 10,686 208,945 205,687 Less: accumulated depreciation and amortization (91,986) (88,915) Total property, plant and equipment, net $ 116,959 $ 116,772 Depreciation and amortization expense related to property, plant and equipment, net, was $3.1 million and $3.0 million for the three months ended March 31, 2022 and 2021, respectively.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities	Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Accrued expenses and other liabilities and other long-term liabilities are comprised of the following: (in thousands) March 31, December 31, Compensation and benefits $ 10,629 $ 22,730 Freight, distribution and operations 26,581 16,157 Accrued rebates, discounts and chargebacks 10,793 10,977 Accrued professional fees 3,596 2,850 Short-term contingent liability (Note 4) 83,300 — Other 7,497 5,354 Total accrued expenses and other liabilities $ 142,396 $ 58,068 Operating lease liabilities (Note 16) $ 16,207 $ 16,546 Long-term contingent liability (Note 4) 20,900 86,200 Other long-term liabilities 21,669 22,148 Total other long-term liabilities $ 58,776 $ 124,894

Sale of Puerto Rico Subsidiary

Sale of Puerto Rico Subsidiary	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Sale of Puerto Rico Subsidiary	Sale of Puerto Rico SubsidiaryDuring the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021. The purchase price for the stock sale was $18.0 million in cash, including a holdback amount of $1.8 million which the Company received during the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA. The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements. The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale): (in thousands) January 29, 2021 Current Assets: Cash and cash equivalents $ 540 Accounts receivable, net 1,959 Inventory 530 Other current assets 65 Total current assets 3,094 Non-Current Assets: Property, plant & equipment, net 780 Intangibles, net 96 Other long-term assets 774 Total assets held for sale $ 4,744 Current Liabilities: Accounts payable $ 185 Accrued expense and other liabilities 369 Total current liabilities 554 Non-Current Liabilities: Asset retirement obligations 306 Other long-term liabilities 588 Total liabilities held for sale $ 1,448 The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statements of operations for the three months ended March 31, 2021.

Asset Retirement Obligations

Asset Retirement Obligations	3 Months Ended
	Mar. 31, 2022
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligations	Asset Retirement Obligations The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of March 31, 2022, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million. The following table provides a summary of the changes in the Company’s asset retirement obligations: (in thousands) Amount Balance at January 1, 2022 $ 20,833 Accretion expense 388 Accelerated Costs 293 Balance at March 31, 2022 $ 21,514 In December 2021, the Company evaluated the accretion timeline of an asset group due to a revision in the planned period of use at the North Billerica site. As a result of the accelerated timeline, the Company determined the asset group’s present value exceeded the current value recorded as of December 31, 2021. Accordingly, the Company recorded a non-cash adjustment of $5.3 million to anticipate a revision in the end of useful life by the end of 2022. The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities upon closure, although the Company has no current plans to close the facilities. The Company has provided this financial assurance in the form of a $28.2 million surety bond.

Intangibles, Net

Intangibles, Net	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, Net	Intangibles, Net Intangibles, net, consisted of the following: March 31, 2022 (in thousands) Useful Lives Amortization Method Cost Accumulated Amortization Net Trademarks 15 - 25 Straight-Line $ 13,540 $ (11,648) $ 1,892 Customer relationships 15 - 25 Accelerated 96,962 (94,856) 2,106 Currently marketed products 9 - 15 Straight-Line 275,700 (29,416) 246,284 Licenses 11 - 16 Straight-Line 85,800 (13,441) 72,359 Developed technology 9 Straight-Line 2,400 (477) 1,923 IPR&D N/A N/A 15,640 — 15,640 Total $ 490,042 $ (149,838) $ 340,204 December 31, 2021 (in thousands) Useful Lives Amortization Method Cost Accumulated Amortization Net Trademarks 15 - 25 Straight-Line $ 13,540 $ (11,510) $ 2,030 Customer relationships 15 - 25 Accelerated 96,880 (94,630) 2,250 Currently marketed product 9 - 15 Straight-Line 275,700 (23,345) 252,355 Licenses 11 - 16 Straight-Line 85,800 (11,555) 74,245 Developed technology 9 Straight-Line 2,400 (410) 1,990 IPR&D N/A N/A 15,640 — 15,640 Total $ 489,960 $ (141,450) $ 348,510 The Company recorded amortization expense for its intangible assets of $8.3 million and $4.7 million for the three months ended March 31, 2022 and 2021, respectively. In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset. The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets: (in thousands) Amount Remainder of 2022 $ 24,923 2023 32,634 2024 32,563 2025 32,508 2026 32,497 2027 and thereafter 169,439 Total $ 324,564

Long-Term Debt, Net, and Other

Long-Term Debt, Net, and Other Borrowings	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt, Net, and Other Borrowings	Long-Term Debt, Net, and Other Borrowings As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows: (in thousands) Amount Remainder of 2022 $ 8,750 2023 15,000 2024 148,750 Total principal outstanding 172,500 Unamortized debt discount (448) Unamortized debt issuance costs (387) Finance lease liabilities 582 Total 172,247 Less: current portion (12,878) Total long-term debt, net and other borrowings $ 159,369 At March 31, 2022, the Company’s interest rate under the five-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility” and the loans thereunder, the “2019 Term Loans”) was 2.2%. On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the original $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.

Derivative Instruments

Derivative Instruments	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative Instruments The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At March 31, 2022, accumulated other comprehensive income included $1.0 million of pre-tax deferred gains that are expected to be reclassified to earnings during the next 12 months. The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets: (in thousands) March 31, 2022 December 31, 2021 Derivatives type Classification Assets: Interest rate swap Other long-term assets $ 3,387 $ 357

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following: (in thousands) Foreign currency translation Unrealized loss on cash flow hedges Accumulated other comprehensive loss Balance at January 1, 2022 $ (754) $ 269 $ (485) Other comprehensive income before reclassifications 140 2,086 2,226 Amounts reclassified to earnings — 170 170 Balance at March 31, 2022 $ (614) $ 2,525 $ 1,911 Balance at January 1, 2021 $ (630) $ (1,418) $ (2,048) Other comprehensive loss before reclassifications 102 533 635 Amounts reclassified to earnings — 173 173 Balance at March 31, 2021 $ (528) $ (712) $ (1,240)

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended (in thousands) 2022 2021 Cost of goods sold $ 912 $ 622 Sales and marketing 1,013 350 General and administrative 3,002 1,920 Research and development 696 425 Total stock-based compensation expense $ 5,623 $ 3,317

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases Operating and finance lease assets and liabilities are as follows: (in thousands) Classification March 31, December 31, Assets Operating Other long-term assets $ 8,675 $ 8,788 Finance Property, plant and equipment, net 602 556 Total leased assets $ 9,277 $ 9,344 Liabilities Current Operating Accrued expenses and other liabilities $ 1,619 $ 1,599 Finance Current portion of long-term debt and other borrowings 378 392 Noncurrent Operating Other long-term liabilities 16,207 16,546 Finance Long-term debt, net and other borrowings 204 299 Total leased liabilities $ 18,408 $ 18,836
Leases	Leases Operating and finance lease assets and liabilities are as follows: (in thousands) Classification March 31, December 31, Assets Operating Other long-term assets $ 8,675 $ 8,788 Finance Property, plant and equipment, net 602 556 Total leased assets $ 9,277 $ 9,344 Liabilities Current Operating Accrued expenses and other liabilities $ 1,619 $ 1,599 Finance Current portion of long-term debt and other borrowings 378 392 Noncurrent Operating Other long-term liabilities 16,207 16,546 Finance Long-term debt, net and other borrowings 204 299 Total leased liabilities $ 18,408 $ 18,836

Net Income Per Common Share

Net Income Per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income Per Common Share	Net Income Per Common Share A summary of net income per common share is presented below: Three Months Ended (in thousands, except per share amounts) 2022 2021 Net income $ 42,962 $ 9,008 Basic weighted-average common shares outstanding 68,008 67,094 Effect of dilutive stock options 406 82 Effect of dilutive restricted stock 1,637 538 Diluted weighted-average common shares outstanding 70,051 67,714 Basic income per common share $ 0.63 $ 0.13 Diluted income per common share $ 0.61 $ 0.13 Antidilutive securities excluded from diluted net income per common share 377 1,349

Other Income

Other Income	3 Months Ended
	Mar. 31, 2022
Other Income and Expenses [Abstract]
Other Income	Other Income Other income consisted of the following: Three Months Ended (in thousands) 2022 2021 Foreign currency (gains) losses $ (81) $ 42 Tax indemnification income, net (396) (573) Interest income (8) (17) Other — (1) Total other income $ (485) $ (549)

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements. As of March 31, 2022, the Company did not have any material ongoing litigation in which the Company was a party. During the first quarter of 2022, the Company was able to resolve certain litigation matters as set forth below: On January 31, 2022, the Company entered into a global settlement agreement with Novartis, AAA, Endocyte and certain of their affiliates to settle certain disputes between the parties, as further described below: German PSMA-617 Litigation On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court” and, such litigation, the “German Litigation”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, a wholly owned subsidiary of Novartis, filed a motion to intervene in the German Litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings. In connection with this dispute, MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) for certain U.S. patent applications filed by the University to support MIPs claim that it is the co-owner of these pending U.S. patent applications (the “Ownership Claim”). On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter. MIP filed a Notice of Appeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021 and an oral hearing for the appeal was scheduled for September 28, 2022, at the Higher Regional Court Karlsruhe. Pursuant to the terms of the Novartis Agreement, the German Litigation was dismissed and the Ownership Claim withdrawn. Post-Grant Review Proceeding On February 4, 2021, AAA, a wholly-owned subsidiary of Novartis and parent of Endocyte, filed a petition for post-grant review of U.S. Patent No. 10,640,461 (the “’461 patent”) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO. The ’461 patent is owned by MIP. In the petition, AAA challenged the patentability of certain claims of the ’461 patent. The PTAB instituted Post-Grant Review proceedings (the “PGR Proceeding”) on July 29, 2021. Pursuant to the terms of the Novartis Agreement, the PGR Proceeding was terminated. Global Settlement Agreement In addition to the dismissal of the German Litigation, the withdrawal of the Ownership Claim and the termination of the PGR Proceeding, under the Novartis Agreement, the parties, among other things, cross-licensed certain patent rights to one another, and Novartis made a $24.0 million lump sum payment to the Company and also reimbursed the Company for certain fees and expenses the Company is required to pay to the University in connection with the German Litigation. The Company received the $24.0 million payment in April 2022. RELISTOR European Opposition Proceedings

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment InformationIn the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Note 1, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022.
Recent Accounting Pronouncements	Recent Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2022

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following table summarizes revenue by revenue source as follows: Three Months Ended Major Products/Service Lines (in thousands) 2022 2021 Product revenue, net (1) $ 180,009 $ 87,319 License and royalty revenues (2) 28,871 5,190 Total revenues $ 208,880 $ 92,509 ________________________________ (1) The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products. (2) The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement. Three Months Ended (in thousands) 2022 2021 DEFINITY $ 58,328 $ 55,971 TechneLite 22,605 22,800 Other precision diagnostics 5,265 6,984 Total precision diagnostics 86,198 85,755 PYLARIFY 92,777 — Other radiopharmaceutical oncology 1,327 1,500 Total radiopharmaceutical oncology 94,104 1,500 Strategic partnerships and other revenue 28,578 5,254 Total revenues $ 208,880 $ 92,509

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis: March 31, 2022 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 38,986 $ 38,986 $ — $ — Interest rate swaps 3,387 — 3,387 — Contingent receivable 8,900 — — 8,900 Total assets $ 51,273 $ 38,986 $ 3,387 $ 8,900 Liabilities: Contingent consideration liabilities $ 104,200 $ — $ — $ 104,200 Total liabilities $ 104,200 $ — $ — $ 104,200 December 31, 2021 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 40,140 $ 40,140 $ — $ — Interest rate swaps 357 — 357 — Contingent receivable 9,300 — — 9,300 Total assets $ 49,797 $ 40,140 $ 357 $ 9,300 Liabilities: Contingent consideration liabilities $ 86,200 $ — $ — $ 86,200 Total liabilities $ 86,200 $ — $ — $ 86,200
Fair value measurement inputs and valuation techniques	The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022. Fair Value at Assumptions (in thousands) March 31, 2022 December 31, 2021 Valuation Technique Unobservable Input March 31, 2022 December 31, 2021 Contingent receivable: Regulatory milestone $ 2,500 $ 2,500 Probability adjusted discounted cash flow model Period of expected milestone achievement 2022 2022 Probability of success 70 % 70 % Discount rate 18 % 17 % Royalties 6,400 6,800 Probability adjusted discounted cash flow model Probability of success 10% - 60% 10% - 60% Discount rate 18 % 17 % Total $ 8,900 $ 9,300 Fair Value at Assumptions (in thousands) March 31, 2022 December 31, 2021 Valuation Technique Unobservable Input March 31, 2022 December 31, 2021 Contingent consideration liability: Net sales targets - PYLARIFY (CVRs) $ 91,700 $ 73,200 Monte Carlo simulation Period of expected milestone achievement and sales targets 2022 - 2023 2022 - 2023 Discount rate 18 % 17 % 1095 commercialization milestone 1,800 1,900 Probability adjusted discounted cash flow model Period of expected milestone achievement 2026 2026 Probability of success 40 % 40 % Discount rate 2.1 % 1.3 % Net sales targets - AZEDRA and 1095 10,700 11,100 Monte Carlo simulation Probability of success and sales targets 40% - 100% 40% - 100% Discount rate 17% - 18% 16% - 17% Total $ 104,200 $ 86,200
Schedule of financial instruments with significant Level 3 inputs	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated: Financial Assets Financial Liabilities (in thousands) Three Months Ended Three Months Ended 2022 2021 2022 2021 Fair value, beginning of period $ 9,300 $ 11,300 $ 86,200 $ 15,800 Changes in fair value included in net income (400) 900 18,000 1,200 Fair value, end of period $ 8,900 $ 12,200 $ 104,200 $ 17,000

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of income tax expense	Three Months Ended (in thousands) 2022 2021 Income tax expense $ 14,939 $ 5,334

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of inventory	Inventory consisted of the following: (in thousands) March 31, December 31, Raw materials $ 13,861 $ 15,505 Work in process 13,071 13,042 Finished goods 7,317 6,582 Total inventory $ 34,249 $ 35,129

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: (in thousands) March 31, December 31, Land $ 13,450 $ 13,450 Buildings 73,560 73,559 Machinery, equipment and fixtures 84,983 83,608 Computer software 24,766 24,384 Construction in progress 12,186 10,686 208,945 205,687 Less: accumulated depreciation and amortization (91,986) (88,915) Total property, plant and equipment, net $ 116,959 $ 116,772

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of accrued liabilities	Accrued expenses and other liabilities and other long-term liabilities are comprised of the following: (in thousands) March 31, December 31, Compensation and benefits $ 10,629 $ 22,730 Freight, distribution and operations 26,581 16,157 Accrued rebates, discounts and chargebacks 10,793 10,977 Accrued professional fees 3,596 2,850 Short-term contingent liability (Note 4) 83,300 — Other 7,497 5,354 Total accrued expenses and other liabilities $ 142,396 $ 58,068 Operating lease liabilities (Note 16) $ 16,207 $ 16,546 Long-term contingent liability (Note 4) 20,900 86,200 Other long-term liabilities 21,669 22,148 Total other long-term liabilities $ 58,776 $ 124,894

Sale of Puerto Rico Subsidiary

Sale of Puerto Rico Subsidiary (Tables)	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Disposal groups including discontinued operations	The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale): (in thousands) January 29, 2021 Current Assets: Cash and cash equivalents $ 540 Accounts receivable, net 1,959 Inventory 530 Other current assets 65 Total current assets 3,094 Non-Current Assets: Property, plant & equipment, net 780 Intangibles, net 96 Other long-term assets 774 Total assets held for sale $ 4,744 Current Liabilities: Accounts payable $ 185 Accrued expense and other liabilities 369 Total current liabilities 554 Non-Current Liabilities: Asset retirement obligations 306 Other long-term liabilities 588 Total liabilities held for sale $ 1,448

Asset Retirement Obligations (T

Asset Retirement Obligations (Tables)	3 Months Ended
	Mar. 31, 2022
Asset Retirement Obligation Disclosure [Abstract]
Summary of changes in asset retirement obligations	The following table provides a summary of the changes in the Company’s asset retirement obligations: (in thousands) Amount Balance at January 1, 2022 $ 20,833 Accretion expense 388 Accelerated Costs 293 Balance at March 31, 2022 $ 21,514

Intangibles, Net (Tables)

Intangibles, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangibles	Intangibles, net, consisted of the following: March 31, 2022 (in thousands) Useful Lives Amortization Method Cost Accumulated Amortization Net Trademarks 15 - 25 Straight-Line $ 13,540 $ (11,648) $ 1,892 Customer relationships 15 - 25 Accelerated 96,962 (94,856) 2,106 Currently marketed products 9 - 15 Straight-Line 275,700 (29,416) 246,284 Licenses 11 - 16 Straight-Line 85,800 (13,441) 72,359 Developed technology 9 Straight-Line 2,400 (477) 1,923 IPR&D N/A N/A 15,640 — 15,640 Total $ 490,042 $ (149,838) $ 340,204 December 31, 2021 (in thousands) Useful Lives Amortization Method Cost Accumulated Amortization Net Trademarks 15 - 25 Straight-Line $ 13,540 $ (11,510) $ 2,030 Customer relationships 15 - 25 Accelerated 96,880 (94,630) 2,250 Currently marketed product 9 - 15 Straight-Line 275,700 (23,345) 252,355 Licenses 11 - 16 Straight-Line 85,800 (11,555) 74,245 Developed technology 9 Straight-Line 2,400 (410) 1,990 IPR&D N/A N/A 15,640 — 15,640 Total $ 489,960 $ (141,450) $ 348,510
Schedule of intangibles	Intangibles, net, consisted of the following: March 31, 2022 (in thousands) Useful Lives Amortization Method Cost Accumulated Amortization Net Trademarks 15 - 25 Straight-Line $ 13,540 $ (11,648) $ 1,892 Customer relationships 15 - 25 Accelerated 96,962 (94,856) 2,106 Currently marketed products 9 - 15 Straight-Line 275,700 (29,416) 246,284 Licenses 11 - 16 Straight-Line 85,800 (13,441) 72,359 Developed technology 9 Straight-Line 2,400 (477) 1,923 IPR&D N/A N/A 15,640 — 15,640 Total $ 490,042 $ (149,838) $ 340,204 December 31, 2021 (in thousands) Useful Lives Amortization Method Cost Accumulated Amortization Net Trademarks 15 - 25 Straight-Line $ 13,540 $ (11,510) $ 2,030 Customer relationships 15 - 25 Accelerated 96,880 (94,630) 2,250 Currently marketed product 9 - 15 Straight-Line 275,700 (23,345) 252,355 Licenses 11 - 16 Straight-Line 85,800 (11,555) 74,245 Developed technology 9 Straight-Line 2,400 (410) 1,990 IPR&D N/A N/A 15,640 — 15,640 Total $ 489,960 $ (141,450) $ 348,510
Schedule of expected future amortization expense	The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets: (in thousands) Amount Remainder of 2022 $ 24,923 2023 32,634 2024 32,563 2025 32,508 2026 32,497 2027 and thereafter 169,439 Total $ 324,564

Long-Term Debt, Net, and Othe_2

Long-Term Debt, Net, and Other Borrowings (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of maturities of principal obligations	As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows: (in thousands) Amount Remainder of 2022 $ 8,750 2023 15,000 2024 148,750 Total principal outstanding 172,500 Unamortized debt discount (448) Unamortized debt issuance costs (387) Finance lease liabilities 582 Total 172,247 Less: current portion (12,878) Total long-term debt, net and other borrowings $ 159,369

Derivative Instruments (Tables)

Derivative Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative instruments	The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets: (in thousands) March 31, 2022 December 31, 2021 Derivatives type Classification Assets: Interest rate swap Other long-term assets $ 3,387 $ 357

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of accumulated other comprehensive income (loss)	The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following: (in thousands) Foreign currency translation Unrealized loss on cash flow hedges Accumulated other comprehensive loss Balance at January 1, 2022 $ (754) $ 269 $ (485) Other comprehensive income before reclassifications 140 2,086 2,226 Amounts reclassified to earnings — 170 170 Balance at March 31, 2022 $ (614) $ 2,525 $ 1,911 Balance at January 1, 2021 $ (630) $ (1,418) $ (2,048) Other comprehensive loss before reclassifications 102 533 635 Amounts reclassified to earnings — 173 173 Balance at March 31, 2021 $ (528) $ (712) $ (1,240)

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense recognized	The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended (in thousands) 2022 2021 Cost of goods sold $ 912 $ 622 Sales and marketing 1,013 350 General and administrative 3,002 1,920 Research and development 696 425 Total stock-based compensation expense $ 5,623 $ 3,317

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of operating and finance lease assets and liabilities	Operating and finance lease assets and liabilities are as follows: (in thousands) Classification March 31, December 31, Assets Operating Other long-term assets $ 8,675 $ 8,788 Finance Property, plant and equipment, net 602 556 Total leased assets $ 9,277 $ 9,344 Liabilities Current Operating Accrued expenses and other liabilities $ 1,619 $ 1,599 Finance Current portion of long-term debt and other borrowings 378 392 Noncurrent Operating Other long-term liabilities 16,207 16,546 Finance Long-term debt, net and other borrowings 204 299 Total leased liabilities $ 18,408 $ 18,836

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary of net income per common share	A summary of net income per common share is presented below: Three Months Ended (in thousands, except per share amounts) 2022 2021 Net income $ 42,962 $ 9,008 Basic weighted-average common shares outstanding 68,008 67,094 Effect of dilutive stock options 406 82 Effect of dilutive restricted stock 1,637 538 Diluted weighted-average common shares outstanding 70,051 67,714 Basic income per common share $ 0.63 $ 0.13 Diluted income per common share $ 0.61 $ 0.13 Antidilutive securities excluded from diluted net income per common share 377 1,349

Other Income (Tables)

Other Income (Tables)	3 Months Ended
	Mar. 31, 2022
Other Income and Expenses [Abstract]
Schedule of other loss (income)	Other income consisted of the following: Three Months Ended (in thousands) 2022 2021 Foreign currency (gains) losses $ (81) $ 42 Tax indemnification income, net (396) (573) Interest income (8) (17) Other — (1) Total other income $ (485) $ (549)

Basis of Presentation (Details)

Basis of Presentation (Details) $ / shares in Units, $ in Thousands	Feb. 20, 2020USD ($)contingent_value_right$ / sharesshares	Mar. 31, 2022USD ($)$ / shares	Dec. 31, 2021USD ($)$ / shares	Jun. 19, 2020$ / shares
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Contingent consideration liabilities | $		$ 104,200	$ 86,200
Business combination, consideration transferred, equity interests issued (in shares) | shares	26,844,877
Business combination common stock under contingent value right (in shares) | shares	86,630,633
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0013
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares to be received from acquisition conversion (in shares) | shares	0.31
Number of CVRs | contingent_value_right	1
Aggregate cash payments percentage	40.00%
Percentage of total contingent consideration under CVRs	19.90%
Business combination contingent value right of total consideration | $	$ 100,000
Share price (in dollars per share) | $ / shares				$ 4.42
Progenics | Cash Payments 2022
Business Acquisition [Line Items]
Contingent consideration liabilities | $	100,000
Progenics | Cash Payments 2023
Business Acquisition [Line Items]
Contingent consideration liabilities | $	$ 150,000

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 208,880	$ 92,509
Total amount awarded	24,000
Product revenue, net
Disaggregation of Revenue [Line Items]
Revenues	180,009	87,319
License and royalty revenues(2)
Disaggregation of Revenue [Line Items]
Revenues	28,871	5,190
Total precision diagnostics
Disaggregation of Revenue [Line Items]
Revenues	86,198	85,755
DEFINITY
Disaggregation of Revenue [Line Items]
Revenues	58,328	55,971
TechneLite
Disaggregation of Revenue [Line Items]
Revenues	22,605	22,800
Other precision diagnostics
Disaggregation of Revenue [Line Items]
Revenues	5,265	6,984
PYLARIFY
Disaggregation of Revenue [Line Items]
Revenues	92,777	0
Other radiopharmaceutical oncology
Disaggregation of Revenue [Line Items]
Revenues	1,327	1,500
Total radiopharmaceutical oncology
Disaggregation of Revenue [Line Items]
Revenues	94,104	1,500
Strategic partnerships and other revenue
Disaggregation of Revenue [Line Items]
Revenues	$ 28,578	$ 5,254

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	$ 8,900	$ 9,300
Total assets	51,273	49,797
Contingent consideration liabilities	104,200	86,200
Total liabilities	104,200	86,200
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	0
Total assets	38,986	40,140
Contingent consideration liabilities	0	0
Total liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	0
Total assets	3,387	357
Contingent consideration liabilities	0	0
Total liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	8,900	9,300
Total assets	8,900	9,300
Contingent consideration liabilities	104,200	86,200
Total liabilities	104,200	86,200
Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	3,387	357
Interest rate swaps | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	0	0
Interest rate swaps | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	3,387	357
Interest rate swaps | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	0	0
Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	38,986	40,140
Money market | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	38,986	40,140
Money market | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Money market | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Narrative (Details) $ in Thousands	Feb. 20, 2020USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Company acquired right to receive certain future milestone		$ 208,880	$ 92,509
Contingent consideration liabilities		$ 104,200		$ 86,200
Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Royalty percentage		0.05
Aggregate cash payments percentage	40.00%
Potential payments, high	$ 100,000	$ 85,000
Progenics | Current Liabilities
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities		83,300
Progenics | Noncurrent Liabilities
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities		8,400
Progenics | Cash Payments 2022
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	100,000
Progenics | Cash Payments 2023
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 150,000
Progenics | Net Sales Targets For Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		70,000
Progenics | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		5,000
Progenics | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payment not reasonably possible		10,000
Royalty | Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Company acquired right to receive certain future milestone		$ 5,000

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) $ in Thousands	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	$ 8,900	$ 9,300
Contingent consideration liabilities	104,200	86,200
Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	8,900	9,300
Contingent consideration liabilities	104,200	86,200
Level 3 | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	2,500	2,500
Level 3 | Royalties
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	6,400	6,800
Level 3 | CVRs
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	91,700	73,200
Level 3 | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	1,800	1,900
Level 3 | Net sales targets - AZEDRA and 1095
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 10,700	$ 11,100
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.70	0.70
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.10	0.10
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.60	0.60
Level 3 | Probability adjusted discounted cash flow model | Probability of success | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.40
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.18	0.17
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Royalties
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.18	0.17
Level 3 | Probability adjusted discounted cash flow model | Discount rate | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.021	0.013
Level 3 | Monte Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.40
Level 3 | Monte Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	1	1
Level 3 | Monte Carlo simulation | Discount rate | CVRs
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.18	0.17
Level 3 | Monte Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.17	0.16
Level 3 | Monte Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.18	0.17

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Financial Assets
Fair value, beginning of period	$ 9,300	$ 11,300
Changes in fair value included in net income	(400)	900
Fair value, end of period	8,900	12,200
Financial Liabilities
Fair value, beginning of period	86,200	15,800
Changes in fair value included in net income	18,000	1,200
Fair value, end of period	104,200	$ 17,000
Change in fair value of the contingent financial asset and contingent financial liabilities	$ 18,400

Income Taxes (Detail)

Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Valuation Allowance [Line Items]
Income tax expense	$ 14,939	$ 5,334
Goodwill acquired		$ 2,600
UNITED KINGDOM
Valuation Allowance [Line Items]
Deferred tax asset, valuation allowance	1,200
SWEDEN
Valuation Allowance [Line Items]
Deferred tax asset, valuation allowance	$ 2,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Raw materials	$ 13,861	$ 15,505
Work in process	13,071	13,042
Finished goods	7,317	6,582
Total inventory	$ 34,249	35,129
DEFINITY
Inventory [Line Items]
Total inventory		$ 6,100

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 208,945		$ 205,687
Less: accumulated depreciation and amortization	(91,986)		(88,915)
Total property, plant and equipment, net	116,959		116,772
Depreciation and amortization expense	3,100	$ 3,000
Land
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	13,450		13,450
Buildings
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	73,560		73,559
Machinery, equipment and fixtures
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	84,983		83,608
Computer software
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	24,766		24,384
Construction in progress
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 12,186		$ 10,686

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation and benefits	$ 10,629	$ 22,730
Freight, distribution and operations	26,581	16,157
Accrued rebates, discounts and chargebacks	10,793	10,977
Accrued professional fees	3,596	2,850
Short-term contingent liability (Note 4)	83,300	0
Other	7,497	5,354
Total accrued expenses and other liabilities	142,396	58,068
Operating lease liabilities (Note 16)	16,207	16,546
Long-term contingent liability (Note 4)	20,900	86,200
Other long-term liabilities	21,669	22,148
Total other long-term liabilities	$ 58,776	$ 124,894

Sale of Puerto Rico Subsidiar_2

Sale of Puerto Rico Subsidiary (Details) - Puerto Rican Radiopharmacy Servicing Subsidiary - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Jan. 29, 2021
Non-Current Liabilities:
Pre-tax book gain on disposal	$ 15,300
Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group consideration		$ 18,000
Disposal group holdback amount		1,800
Current assets
Cash and cash equivalents		540
Accounts receivable, net		1,959
Inventory		530
Other current assets		65
Total current assets		3,094
Non-Current Assets:
Property, plant & equipment, net		780
Intangibles, net		96
Other long-term assets		774
Total assets held for sale		4,744
Current liabilities
Accounts payable		185
Accrued expense and other liabilities		369
Total current liabilities		554
Non-Current Liabilities:
Asset retirement obligations		306
Other long-term liabilities		588
Total liabilities held for sale		$ 1,448

Asset Retirement Obligations -

Asset Retirement Obligations - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022
Asset Retirement Obligation Disclosure [Abstract]
Obligation expected to be incurred		$ 26.4
Non-cash adjustment	$ 5.3
Financial assurance in form of surety bond		$ 28.2

Asset Retirement Obligations _2

Asset Retirement Obligations - Asset Retirement Obligation (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Asset retirement obligations, beginning balance	$ 20,833
Accretion expense	388
Accelerated Costs	293	$ 0
Asset retirement obligations, ending balance	$ 21,514

Intangibles, Net - Schedule of

Intangibles, Net - Schedule of Intangibles, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Indefinite lived, Cost	$ 15,640		$ 15,640
Total, cost	490,042		489,960
Accumulated Amortization	(149,838)		(141,450)
Total	324,564
Total, net	340,204		348,510
Trademarks
Finite-Lived Intangible Assets [Line Items]
Cost	13,540		13,540
Accumulated Amortization	(11,648)		(11,510)
Total	$ 1,892		2,030
Trademarks | Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	15 years	15 years
Trademarks | Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years	25 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	$ 96,962		96,880
Accumulated Amortization	(94,856)		(94,630)
Total	$ 2,106		2,250
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	15 years	15 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years	25 years
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Cost	$ 275,700		275,700
Accumulated Amortization	(29,416)		(23,345)
Total	$ 246,284		252,355
Currently marketed products | Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	9 years	9 years
Currently marketed products | Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	15 years	15 years
Licenses
Finite-Lived Intangible Assets [Line Items]
Cost	$ 85,800		85,800
Accumulated Amortization	(13,441)		(11,555)
Total	$ 72,359		74,245
Licenses | Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	11 years	11 years
Licenses | Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	16 years	16 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	9 years	9 years
Cost	$ 2,400		2,400
Accumulated Amortization	(477)		(410)
Total	$ 1,923		$ 1,990

Intangibles, Net - Additional I

Intangibles, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 8.3	$ 4.7
IPR & D
Finite-Lived Intangible Assets [Line Items]
Decrease in indefinite lived assets	132.8
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Increase in finite lived assets	$ 132.8

Intangibles, Net - Schedule o_2

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) $ in Thousands	Mar. 31, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 24,923
2023	32,634
2024	32,563
2025	32,508
2026	32,497
2027 and thereafter	169,439
Total	$ 324,564

Long-Term Debt, Net, and Othe_3

Long-Term Debt, Net, and Other Borrowings (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
2022		$ 8,750,000
2023		15,000,000
2024		148,750,000
Total principal outstanding		172,500,000
Unamortized debt discount		(448,000)
Unamortized debt issuance costs		(387,000)
Finance lease liabilities		582,000
Total		172,247,000
Less: current portion		(12,878,000)
Total long-term debt, net and other borrowings		159,369,000		$ 163,121,000
Gain on extinguishment of debt		$ 0	$ 889,000
Royalty-Backed Loan
Debt Instrument [Line Items]
Debt instrument face amount	$ 50,000,000		$ 50,000,000
Extinguishment of debt	30,900,000
Prepayment of debt	500,000
Gain on extinguishment of debt	$ 900,000
2019 Term Loan Facility
Debt Instrument [Line Items]
Debt instrument term		5 years
Interest rate		2.20%

Derivative Instruments (Detail)

Derivative Instruments (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2020
Derivative [Line Items]
Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months	$ 1,000,000
Cash Flow Hedge | Interest rate swaps
Derivative [Line Items]
Notional amount			$ 100,000,000
Average fixed interest rate			0.82%
Cash Flow Hedge | Interest rate swaps | Other Noncurrent Assets
Derivative [Line Items]
Interest rate swap	$ 3,387,000	$ 357,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, tax	$ 900	$ 200
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	464,439	514,205
Other comprehensive income (loss) before reclassifications	2,226	635
Amounts reclassified to earnings	170	173
Ending balance	515,850	528,119
Foreign currency translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(754)	(630)
Other comprehensive income (loss) before reclassifications	140	102
Amounts reclassified to earnings	0	0
Ending balance	(614)	(528)
Unrealized loss on cash flow hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	269	(1,418)
Other comprehensive income (loss) before reclassifications	2,086	533
Amounts reclassified to earnings	170	173
Ending balance	2,525	(712)
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(485)	(2,048)
Ending balance	$ 1,911	$ (1,240)

Stock-Based Compensation (Detai

Stock-Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,623	$ 3,317
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	912	622
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,013	350
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	3,002	1,920
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 696	$ 425

Leases - Operating and Finance

Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Operating	$ 8,675	$ 8,788
Finance	602	556
Total leased assets	9,277	9,344
Current liabilities
Operating	1,619	1,599
Finance	378	392
Non-Current Liabilities:
Operating lease liabilities (Note 16)	16,207	16,546
Finance	204	299
Total leased liabilities	$ 18,408	$ 18,836
Operating lease, right-of-use asset, statement of financial position [Extensible Enumeration]	Other long-term assets	Other long-term assets
Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating lease, liability, current, statement of financial position [Extensible Enumeration]	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Finance lease, liability, current, statement of financial position [Extensible Enumeration]	Current portion of long-term debt and other borrowings	Current portion of long-term debt and other borrowings
Operating lease, liability, noncurrent, statement of financial position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration]	Long-term debt, net and other borrowings	Long-term debt, net and other borrowings

Net Income Per Common Share (De

Net Income Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net income	$ 42,962	$ 9,008
Basic weighted-average common shares outstanding (in shares)	68,008	67,094
Effect of dilutive stock options (in shares)	406	82
Effect of dilutive restricted stock (in shares)	1,637	538
Diluted weighted-average common shares outstanding (in shares)	70,051	67,714
Basic income per common share (in dollars per share)	$ 0.63	$ 0.13
Diluted income per common share (in dollars per share)	$ 0.61	$ 0.13
Antidilutive securities excluded from diluted net income per common share (in shares)	377	1,349

Other Income (Details)

Other Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other Income and Expenses [Abstract]
Foreign currency (gains) losses	$ (81)	$ 42
Tax indemnification income, net	(396)	(573)
Interest income	(8)	(17)
Other	0	(1)
Total other income	$ (485)	$ (549)

Commitments and Contingencies (

Commitments and Contingencies (Details) € in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2015patent	Mar. 31, 2022USD ($)	Feb. 27, 2019EUR (€)
Loss Contingencies [Line Items]
Total amount awarded | $		$ 24
European
Loss Contingencies [Line Items]
Number of patents | patent	3
MIP
Loss Contingencies [Line Items]
Court deposit | €			€ 0.4

Segment Information (Details)

Segment Information (Details)	3 Months Ended
	Mar. 31, 2022segment
Segment Reporting [Abstract]
Operating segments	1